Ascendis Pharma A (ASND) EPS (Weighted Average and Diluted) (2014 - 2026)

Ascendis Pharma A has disclosed EPS (Weighted Average and Diluted) across 13 years of filings, most recently posting $64.86 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $64.86, up 8.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.86 (up 8.22% YoY), and the FY2025 annual result was -$4.38, up 37.28% from the prior year.
• EPS (Weighted Average and Diluted) came in at $64.86 for Q1 2026 at Ascendis Pharma A, up from -$9.06 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $64.86 in Q1 2026 to a low of -$30.22 in Q4 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$7.47 (2024), against an average of $7.47.
• Across the five-year window, EPS (Weighted Average and Diluted) jumped 172.39% in 2024 and plunged 216.15% in 2025, its largest moves.
• Ascendis Pharma A's EPS (Weighted Average and Diluted) stood at -$30.22 in 2022, then surged by 55.17% to -$13.55 in 2023, then surged by 56.51% to -$5.89 in 2024, then tumbled by 53.73% to -$9.06 in 2025, then surged by 816.19% to $64.86 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $64.86 (Q1 2026), -$9.06 (Q4 2025), and -$19.43 (Q3 2025), per Business Quant data.